IRD Key Statistics, Chart & Performance
The current stock price of IRD is 2.04 USD. In the past month the price increased by 3.03%. In the past year, price increased by 72.88%.
IRD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.33 | 406.30B | ||
| AMGN | AMGEN INC | 15.27 | 179.83B | ||
| GILD | GILEAD SCIENCES INC | 15.34 | 155.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.67 | 117.47B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.41 | 82.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.67 | 52.94B | ||
| INSM | INSMED INC | N/A | 37.84B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.53 | 25.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.5 | 22.16B | ||
| INCY | INCYTE CORP | 15.64 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About IRD
Company Profile
Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 18 full-time employees. The company went IPO on 2004-11-30. The firm is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Company Info
OPUS GENETICS INC
8 Davis Drive, Suite 220
Durham NORTH CAROLINA US
Employees: 18
Phone: 12486819815
OPUS GENETICS INC / IRD FAQ
Can you describe the business of OPUS GENETICS INC?
Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 18 full-time employees. The company went IPO on 2004-11-30. The firm is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
What is the stock price of OPUS GENETICS INC today?
The current stock price of IRD is 2.04 USD. The price increased by 1.49% in the last trading session.
What is the dividend status of OPUS GENETICS INC?
IRD does not pay a dividend.
How is the ChartMill rating for OPUS GENETICS INC?
IRD has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in OPUS GENETICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IRD.
Is OPUS GENETICS INC (IRD) expected to grow?
The Revenue of OPUS GENETICS INC (IRD) is expected to grow by 49.68% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
When does OPUS GENETICS INC (IRD) report earnings?
OPUS GENETICS INC (IRD) will report earnings on 2026-03-30, after the market close.
IRD Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to IRD. When comparing the yearly performance of all stocks, IRD is one of the better performing stocks in the market, outperforming 92.1% of all stocks.
IRD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IRD. Both the profitability and financial health of IRD have multiple concerns.
IRD Financial Highlights
Over the last trailing twelve months IRD reported a non-GAAP Earnings per Share(EPS) of -0.83. The EPS increased by 23.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -188.81% | ||
| ROE | -1143% | ||
| Debt/Equity | 0.18 |
IRD Forecast & Estimates
For the next year, analysts expect an EPS growth of 34.94% and a revenue growth 49.68% for IRD